Epstein barr virus in gastric carcinoma risk factor

Reading File

Searching PubMed

Epstein-Barr virus gastric carcinoma risk factors

Finding Sources

Reading Article

PMID: 40234237

Reading File

Searching Images

Epstein-Barr virus gastric carcinoma in situ hybridization EBV positive

This composite image illustrates the clinical and histopathological findings of Epstein-Barr virus-associated gastric cancer (EBVaGC). Panel (a) shows an ordinary endoscopic view of the middle gastric body, identifying a superficial depressed-type early gastric cancer lesion (indicated by a yellow arrow). Panel (b) depicts the lesion during endoscopic submucosal dissection (ESD) using en bloc resection. Panel (c) is a low-power microscopic view of the H&E-stained ESD specimen, demonstrating submucosal invasion (0.8 mm) and a carcinoma with lymphoid stroma (CLS) pattern without lymphovascular involvement. Panel (d) shows a high-power microscopic view using EBER-1 in situ hybridization (ISH); the tumor cell nuclei exhibit strong positive (dark) staining for EBV-encoded RNA, while surrounding tumor-infiltrating lymphocytes (TILs) and non-cancerous gastric epithelium remain negative. This case demonstrates the diagnosis and therapeutic evaluation of EBVaGC, emphasizing the use of ISH for definitive classification in early-stage mucosal lesions.

A multi-panel clinical and diagnostic figure demonstrating Epstein-Barr virus-associated gastric cancer (EBVaGC). Panel (a) is an endoscopic clinical photograph showing a gastric lesion near the cardia, characterized by a depressed morphology and a submucosal tumor (SMT)-like protrusion (marked by a yellow arrow). Panel (b) shows the macroscopic specimen from a total gastrectomy, displayed on a blue background with a 10 mm scale bar. The lesion (yellow arrow) is situated in the upper stomach near the gastric mucosal atrophic border, which is demarcated by yellow lines. Panel (c) is a histopathology image showing EBER-1 in situ hybridization (ISH). The image displays numerous tumor cell nuclei with positive dark purple staining, characteristic of carcinoma with lymphoid stroma (CLS) associated with EBV. The educational focus is on the endoscopic and macroscopic identification of EBVaGC, highlighting its typical location in the upper stomach and its distinctive histological signature.

I now have comprehensive material to compose a detailed, well-cited answer.

Epstein-Barr Virus (EBV) in Gastric Carcinoma - Risk Factors & Pathogenesis

Epidemiology

EBV-associated gastric carcinoma (EBVaGC) accounts for approximately 9-10% of all gastric adenocarcinomas worldwide, with an estimated 80,000 new cases per year globally. It is recognized as a distinct molecular subtype by The Cancer Genome Atlas (TCGA). - Yamada's Textbook of Gastroenterology, 7th ed.

Established Risk Factors for EBVaGC

1. EBV Infection Itself

EBV is the most direct risk factor. A 2025 meta-analysis (PMID 40234237) found:

EBV infection alone: OR 4.98 (95% CI 3.17-7.85) for developing gastric cancer vs. non-infected controls
H. pylori + EBV co-infection: OR 2.57 (95% CI 1.65-4.01) - a 2.57-fold elevated risk, suggesting synergistic interaction

The EBV episomes in gastric tumors are clonal, meaning viral infection precedes neoplastic transformation - not the reverse. - Robbins & Kumar Basic Pathology

2. H. pylori Co-infection

H. pylori is the most important overall gastric cancer risk factor (WHO Group 1 carcinogen, ~75% of all gastric cancers), and its co-infection with EBV amplifies risk further. H. pylori-induced chronic inflammation, mucosal atrophy, and intestinal metaplasia create a permissive microenvironment for EBV-driven oncogenesis. - Sabiston Textbook of Surgery, 21st ed.

3. Male Sex

EBVaGC shows a strong male predominance, occurring significantly more often in men than women. This is a consistent demographic feature across multiple population studies. - Yamada's Textbook of Gastroenterology

4. Prior Gastric Surgery (Remnant Stomach)

Patients who have undergone prior gastric surgery are at elevated risk for EBVaGC. The remnant stomach after partial gastrectomy appears particularly susceptible to EBV-associated transformation, possibly due to altered mucosal immunity and reflux of bile/intestinal contents.

5. Proximal Stomach Location

EBV-positive tumors preferentially arise in the proximal stomach (cardia/fundus/body), unlike H. pylori-associated cancers which tend to be antral. - Robbins & Kumar Basic Pathology

Molecular Mechanisms of EBV-Driven Carcinogenesis

EBV alters host cell biology through several key mechanisms:

Mechanism	Effect
EBV microRNAs	Suppress host tumor suppressor gene expression
CpG island hypermethylation	Epigenetic silencing of tumor suppressor genes (extreme DNA hypermethylation - the most methylated of all GC subtypes)
PIK3CA mutations	Recurrent activating mutations driving PI3K/AKT/mTOR pathway
JAK2 / CD274 / PDCD1LG2 amplification	Overexpression of PD-L1/PD-L2 - immune checkpoint upregulation enabling immune evasion
EBER (EBV-encoded small RNA)	Detected by in situ hybridization (ISH) - the diagnostic hallmark
LMP2A (Latent Membrane Protein 2A)	Mimics BCR signaling, promotes cell survival
TP53 mutations rare	Unlike other GC subtypes, suggesting a distinct pathogenic route

TCGA molecular classification cited in Yamada's Textbook of Gastroenterology; Sabiston Textbook of Surgery

TCGA Molecular Classification (Relevance to EBVaGC)

The Cancer Genome Atlas classified gastric cancer into 4 subtypes:

EBV-positive - recurrent PIK3CA mutations, extreme hypermethylation, JAK2/PD-L1/PD-L2 amplification
Microsatellite unstable (MSI)
Genomically stable (enriched for diffuse type, RHOA mutations)
Chromosomally unstable (CIN)

EBVaGC is the most heavily methylated cancer subtype among all studied, and its high PD-L1 expression makes it potentially responsive to immune checkpoint inhibitors. A 2025 meta-analysis (PMID 40858966) confirmed globally elevated PD-L1 expression in EBVaGC.

Morphological Features (Diagnostic Clues)

Predilection: proximal stomach (cardia, fundus, body)
Growth pattern: typically diffuse
Histology: often carcinoma with lymphoid stroma (lymphoepithelioma-like) - dense TIL infiltrate
Diagnosis confirmed by EBER-1 in situ hybridization (ISH) - strong nuclear positivity in tumor cells

EBVaGC EBER-1 ISH showing strong nuclear staining in tumor cells with carcinoma with lymphoid stroma pattern

EBER-1 in situ hybridization showing dark nuclear positivity in EBV-positive gastric cancer cells, with surrounding lymphocytic infiltrate negative - the diagnostic hallmark of EBVaGC

Complete Risk Factor Summary (Box)

Medical/Infectious

EBV latent infection (OR ~5.0 for GC)
H. pylori infection (OR ~1.4-6x for GC); co-infection synergistic (OR 2.57)
Atrophic gastritis / intestinal metaplasia
Prior gastric surgery

Demographic

Male sex (male predominance in EBVaGC)
Younger age at diagnosis compared to other GC subtypes

Molecular/Genetic

Epigenetic susceptibility (CpG hypermethylation background)
PIK3CA pathway alterations

Environmental (General GC Risk Factors)

Smoked/salted/pickled foods, high nitrate intake
Smoking and alcohol
Low fruit/vegetable intake
Low socioeconomic status, lack of refrigeration
Sabiston Textbook of Surgery, Risk Factors Box 87.1

Clinical Significance

Because EBVaGC has high PD-L1 expression and is heavily infiltrated by T lymphocytes (hot immune microenvironment), it may be particularly susceptible to PD-1/PD-L1 immune checkpoint inhibitor therapy - an active area of clinical research highlighted in the 2024 systematic review (PMID 38669788) on tumor immune composition of EBV-positive and MMR-deficient gastric cancers.

Key takeaway: EBV is an independent and potent risk factor for a distinct molecular subtype of gastric carcinoma, acting through epigenetic reprogramming and immune evasion. Co-infection with H. pylori compounds the risk significantly (2.57-fold OR from 2025 meta-analysis). Male sex and proximal stomach location are defining clinicopathological features.

This is a shared conversation. Sign in to Orris to start your own chat.